Studies on the interaction of Trasylol (aprotinin) with trypsin-pancreatic secretory trypsin inhibitor (PSTI) complexes and with alpha 2-macroglobulin-trypsin-PSTI-complexes.
An investigation was performed to study the interaction of Trasylol with both trypsin-pancreatic secretory trypsin inhibitor (PSTI) and alpha 2-macroglobulin (alpha 2-M)-trypsin-PSTI complexes. Trasylol was readily able to displace immunogenic PSTI from a complex with trypsin in vitro. A similar scale of displacement of PSTI by Trasylol from alpha 2-M-trypsin-PSTI complexes could not be demonstrated. Using complexes manufactured in vitro with 125I-labelled PSTI, we found that only a small percentage of the PSTI label could be liberated, even when presented with amounts of Trasylol in a 10-molar excess to the PSTI.
D007611:Aprotinin / Q000494:pharmacology*; D004347:Drug Interactions; D006801:Humans; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000494:pharmacology*; D014361:Trypsin Inhibitors / Q000494:pharmacology*; D000511:alpha-Macroglobulins / Q000494:pharmacology*
D014361:Trypsin Inhibitors; D000511:alpha-Macroglobulins; D014359:Trypsin Inhibitor, Kazal Pancreatic; D007611:Aprotinin